Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bacterial lipopolysaccharide (LPS) and outer-membrane components are essential structural elements of Gram-negative bacteria that provide a robust permeability barrier against environmental stressors and antibiotics (Raetz & Whitfield, 2002). LPS, often referred to as endotoxin, is composed of a hydrophobic Lipid A anchor, a core oligosaccharide, and a distal O-antigen (Whitfield & Trent, 2014). It serves as a primary trigger for the host innate immune response by binding to the Toll-like receptor 4 (TLR4)/MD-2 complex, which can lead to the release of pro-inflammatory cytokines (Park & Lee, 2013). In clinical settings, excessive LPS release during severe infections can cause systemic inflammation, sepsis, and life-threatening septic shock (Opal, 2010). Therapeutic interventions target these components through various mechanisms, such as the use of polymyxins (Polymyxin B and Colistin) which bind to Lipid A to disrupt the membrane, or novel inhibitors like murepavadin that target the LPS transport protein LptD (Srinivas et al., 2010). Despite their critical role in pathogenesis, developing safe and effective therapies remains difficult due to the risk of nephrotoxicity associated with current drugs and the high failure rate of anti-endotoxin clinical trials (Wiersinga et al., 2014).
Direct binding and neutralization of the Lipid A moiety of LPS to disrupt membrane integrity, inhibition of LPS transport proteins such as LptD to prevent outer membrane assembly, and antagonism of host TLR4 receptors to block endotoxin-induced inflammatory signaling.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bacterial lipopolysaccharide (LPS) and outer-membrane components (LPS/OMC).